Nektar Therapeutics has blamed manufacturing quality problems for falling response rates in a study of patients receiving its immuno-oncology drug bempegaldesleukin.
Early in a Phase I/II trial, the pegylated version of human recombinant interleukin 2 (IL-2), formerly known as NKTR-214, achieved a 63% response rate when given with Bristol-Myers Squibb...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?